Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required 

A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off

Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups 

Results from an exploratory analysis of the IMpower010 trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival 

Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors

From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed

Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation

Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status